会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 23. 发明申请
    • BIOMARKERS FOR AGGRESSIVE PROSTATE CANCER
    • 生物标志物用于肿瘤前列腺癌
    • US20140106369A1
    • 2014-04-17
    • US14006503
    • 2012-03-22
    • Hui ZhangYuan TianDaniel W. ChanJing Chen
    • Hui ZhangYuan TianDaniel W. ChanJing Chen
    • G01N33/68
    • G01N33/6893G01N33/57434
    • The present invention relates to the field of biomarkers and, more specifically, to biomarkers useful in diagnosing aggressive prostate cancer. In specific embodiments, a method for diagnosing aggressive prostate cancer in a patient comprises (a) measuring the levels of one or more biomarkers in a sample collected from the patient; and (b) comparing the levels of the one or more biomarkers with predefined levels of the same biomarkers that correlate to a patient having aggressive prostate cancer and predefined levels of the same biomarkers that correlate to a patient not having aggressive prostate cancer, wherein a correlation to one of the predefined levels provides the diagnosis. In a specific embodiment, the one or more biomarkers may comprise cathepsin-L (CTSL), periostin, microfibrillar-associated protein 4 (MFAP4), collagen XII, neprilysin, clusterin, neutrophil gelatinase associated lipocalin (NGAL), epithelial cell activating molecule (EpCAM), prostate specific antigen (PSA), membrane metallo-endopeptidase (MME) and asporin (ASPN).
    • 本发明涉及生物标记领域,更具体地涉及可用于诊断侵略性前列腺癌的生物标志物。 在具体实施方案中,用于诊断患者中侵袭性前列腺癌的方法包括(a)测量从患者收集的样品中的一种或多种生物标志物的水平; 和(b)将一种或多种生物标志物的水平与与具有侵袭性前列腺癌的患者相关的相同生物标志物的预定水平和与不具有侵袭性前列腺癌的患者相关的相同生物标志物的预定水平进行比较,其中相关性 到其中一个预定义的级别提供诊断。 在一个具体的实施方案中,一种或多种生物标志物可以包含组织蛋白酶-L(CTSL),骨膜素,微原纤维相关蛋白4(MFAP4),胶原XII,起泡蛋白,聚集蛋白,嗜中性粒细胞明胶酶相关脂质运载蛋白(NGAL),上皮细胞活化分子 EpCAM),前列腺特异性抗原(PSA),膜金属内肽酶(MME)和阿泊菌(ASPN)。
    • 24. 发明申请
    • HYBRID POLYURETHANE BLOCK COPOLYMERS WITH THERMOPLASTIC PROCESSABILITY AND THERMOSET PROPERTIES
    • 具有热塑性加工性和热稳定性的混合聚氨酯嵌段共聚物
    • US20110028661A1
    • 2011-02-03
    • US12809212
    • 2008-12-18
    • Robert S. WardKeith R. McCreaYuan TianJim Yang
    • Robert S. WardKeith R. McCreaYuan TianJim Yang
    • C08F283/12
    • C08G18/3228C08G18/4812C08G18/61C08G18/6611
    • Block copolymers are formulated with multifunctional chain extenders. The block copolymers include a soft segment and a hard segment made from a diisocyanate, an alkylene diamine chain extender, and a multifunctional chain extender which provides delayed crosslinking. The multifunctional chain extenders have a functionality and typically have at least one OH group. The multifunctional chain extenders may be aliphatic or aromatic triols or polyols, or may have other configurations, as described. The resulting block copolymers have improved mechanical properties such as compression set. They may be used in medical applications, or in industrial applications such as seal and gasket applications, including O-rings, window seals, and automotive gaskets. The initially-formed polyurethane resin behaves as a thermoplastic processable material, while the configured end-use product is thermoset.
    • 嵌段共聚物用多功能扩链剂配制。 嵌段共聚物包括软链段和由二异氰酸酯制成的硬链段,亚烷基二胺扩链剂和提供延迟交联的多官能扩链剂。 多功能扩链剂具有官能团并且通常具有至少一个OH基团。 多官能增链剂可以是脂族或芳族三醇或多元醇,或者可以具有如所述的其它构型。 所得的嵌段共聚物具有改进的机械性能,如压缩永久变形。 它们可用于医疗应用或工业应用中,例如密封和垫片应用,包括O型圈,窗户密封件和汽车垫圈。 初始形成的聚氨酯树脂表现为热塑性可加工材料,而配置的最终用途产品是热固性的。
    • 27. 发明授权
    • Biomarkers for aggressive prostate cancer
    • 用于侵略性前列腺癌的生物标志物
    • US09594086B2
    • 2017-03-14
    • US14006503
    • 2012-03-22
    • Hui ZhangYuan TianDaniel W. ChanJing Chen
    • Hui ZhangYuan TianDaniel W. ChanJing Chen
    • G01N33/53G01N33/68G01N33/574
    • G01N33/6893G01N33/57434
    • The present invention relates to the field of biomarkers and, more specifically, to biomarkers useful in diagnosing aggressive prostate cancer. In specific embodiments, a method for diagnosing aggressive prostate cancer in a patient comprises (a) measuring the levels of one or more biomarkers in a sample collected from the patient; and (b) comparing the levels of the one or more biomarkers with predefined levels of the same biomarkers that correlate to a patient having aggressive prostate cancer and predefined levels of the same biomarkers that correlate to a patient not having aggressive prostate cancer, wherein a correlation to one of the predefined levels provides the diagnosis. In a specific embodiment, the one or more biomarkers may comprise cathepsin-L (CTSL), periostin, microfibrillar-associated protein 4 (MFAP4), collagen XII, neprilysin, clusterin, neutrophil gelatinase associated lipocalin (NGAL), epithelial cell activating molecule (EpCAM), prostate specific antigen (PSA), membrane metallo-endopeptidase (MME) and asporin (ASPN).
    • 本发明涉及生物标记领域,更具体地涉及可用于诊断侵略性前列腺癌的生物标志物。 在具体实施方案中,用于诊断患者中侵袭性前列腺癌的方法包括(a)测量从患者收集的样品中的一种或多种生物标志物的水平; 和(b)将一种或多种生物标志物的水平与与具有侵袭性前列腺癌的患者相关的相同生物标志物的预定水平和与不具有侵袭性前列腺癌的患者相关的相同生物标志物的预定水平进行比较,其中相关性 到其中一个预定义的级别提供诊断。 在一个具体的实施方案中,一种或多种生物标志物可以包含组织蛋白酶-L(CTSL),骨膜素,微原纤维相关蛋白4(MFAP4),胶原XII,起泡蛋白,聚集蛋白,嗜中性粒细胞明胶酶相关脂质运载蛋白(NGAL),上皮细胞活化分子 EpCAM),前列腺特异性抗原(PSA),膜金属内肽酶(MME)和阿泊菌(ASPN)。
    • 30. 发明申请
    • SILICONE HYDROGELS FOR TISSUE ADHESIVES AND TISSUE DRESSING APPLICATIONS
    • 用于组织粘合剂和组织粘合应用的硅胶水凝胶
    • US20110086077A1
    • 2011-04-14
    • US12745509
    • 2008-11-21
    • Keith R. McCreaRobert S. WardYuan Tian
    • Keith R. McCreaRobert S. WardYuan Tian
    • A61L15/22A61K38/39A61P17/02
    • A61L15/60A61L15/225A61L15/26A61L26/0019A61L26/0076A61L26/008C08L83/04
    • A silicone hydrogel formulation may contains random and/or block copolymers or oligomers or macromers. The silicone copolymer is copolymerized or blended with other polymers or monomers or macromers to obtain final formulation. The silicone hydrogel may contain crosslinking groups to provide a complete or partially crosslinked final structure. The silicone hydrogel formulation may be pre-formed as a film or other structure, or it may be polymerized during application as in the case of an adhesive formulation. A wound dressing comprising a silicone hydrogel formed as a film, either prior to application to a wound or in situ on a wound, which film has gas permeability, moisture permeability, and high water content, wherein said silicone hydrogel is formed from a polymerizable silicone such as a difunctional polydimethylsiloxane methacrylate and crosslinking agents such as N,N-dimethyllacrylamide (DMA), 2-hydroxyethyl methacrylate (HEMA), and trimethylsiloxy silane (TRIS).
    • 硅氧烷水凝胶制剂可以含有无规和/或嵌段共聚物或低聚物或大分子单体。 硅氧烷共聚物与其它聚合物或单体或大分子单体共聚或共混以获得最终配方。 硅氧烷水凝胶可以含有交联基团以提供完全或部分交联的最终结构。 硅氧烷水凝胶制剂可以预先形成为膜或其它结构,或者可以在使用时聚合,如在粘合剂制剂的情况下。 一种伤口敷料,其包含在施加到伤口之前或原位在伤口上形成的膜的硅酮水凝胶,该膜具有透气性,透湿性和高含水量,其中所述硅氧水凝胶由可聚合硅氧烷形成 例如甲基丙烯酸二官能聚二甲基硅氧烷和N,N-二甲基丙烯酰胺(DMA),甲基丙烯酸2-羟乙酯(HEMA)和三甲基甲硅烷氧基硅烷(TRIS)等交联剂。